Fundz

Excellergy secures $70 million in Series A financing to advance innovative allergy treatments. Led by Samsara BioCapital, Red Tree Venture Capital, and Decheng Capital, this funding aims to redefine allergy control.

RECENTLY ACQUIREDOct 13, 2025

Amount Raised

$70 Million

Round Type

Series A

Palo AltoBiotechnologyHealth Care

Investors

Samsara BiocapitalRed Tree Venture CapitalDecheng Capital

Description

Excellergy, a biotechnology company focused on allergy therapeutics, has launched with $70 million in Series A financing. The funds will advance its pipeline of first-in-class Effector Cell Response Inhibitors (ECRIs). With a unique trifunctional mechanism, Excellergy aims to redefine the treatment of allergic diseases. Industry veteran Todd Zavodnick has been appointed as President and CEO to lead the clinical development team.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Excellergy that raised within 45 days of this round, from Fundz verified event records.

  • Yuvrit Ayurveda raised $800K (Seed) on November 27, 2025.
  • Medow Health raised $2.2M (Funding Round) on November 27, 2025.
  • Gosta Labs raised $8.7M (Seed) on November 27, 2025.
  • Noteless raised $4.1M (Seed) on November 27, 2025.
  • Ventuno Biotech raised $3.5M (Seed) on November 27, 2025.
  • SymPhysis Medical raised $1.3M (Grant) on November 26, 2025.

Who to call at Excellergy, and when

A new round usually means Excellergy is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Excellergy raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Excellergy, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Excellergy. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Excellergy

Location

Palo Alto, California, United States

About

Excellergy is a biotechnology company developing a novel class of allergy therapeutics called Effector Cell Response Inhibitors (ECRIs). These agents aim to redefine allergy treatment by providing complete control of allergic responses through innovative mechanisms targeting effector cells. The company leverages scientific advancements to create a new therapeutic category designed to improve the lives of patients suffering from allergic diseases. Excellergy plans to move its lead product into clinical trials in early 2026.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Excellergy raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Excellergy's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Excellergy raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.